Normal AMH and FSH Reference Ranges in Reproductive-Age Women
For FSH, elevation beyond 25 IU/L in a young woman (outside the pre-ovulation peak) indicates premature ovarian insufficiency, with normal values typically remaining below this threshold in reproductive-age women. 1
FSH Reference Values
The most clinically relevant FSH thresholds are defined in the context of ovarian function assessment:
- Normal FSH: Generally <10 IU/L is considered reassuring in fertility evaluation 2
- Borderline elevation: 10-25 IU/L warrants careful interpretation
- Elevated FSH: >25 IU/L indicates premature ovarian insufficiency (POI) in women under 40 years 1
- POI cases average 37 IU/L (range 26-64 IU/L)
- Autoimmune-related POI often shows levels between 25-35 IU/L 1
Critical caveat: FSH must be measured on cycle days 2-4 with estradiol <50 pg/mL to ensure accuracy, as combined hormonal contraception or macro-progestins significantly suppress FSH levels and require 3+ months washout before reliable testing 1, 2.
AMH Reference Ranges
AMH values vary significantly by age and decline progressively throughout reproductive years. Based on large population studies:
Age-Specific Median AMH Values (ng/mL):
- Ages 20-25: 6.23 ng/mL (5th-95th percentile: 2.06-12.66) 3
- Ages 25-30: 5.65 ng/mL (5th-95th percentile: 1.77-13.83) 3
- Ages 30-33: 4.55 ng/mL (5th-95th percentile: 1.48-11.45) 3
- Ages 33-37: 3.74 ng/mL (5th-95th percentile: 0.87-9.76) 3
- Ages 37-40: 2.78 ng/mL (5th-95th percentile: 0.56-9.49) 3
- Ages 40-55: 1.09 ng/mL (5th-95th percentile: 0.08-5.70) 3
Clinical Interpretation Thresholds:
Low AMH (diminished ovarian reserve):
- <0.7-1.1 ng/mL indicates significantly diminished reserve across multiple studies 4
- <0.85 ng/mL used as cutoff in recent European studies 4
Normal/Reassuring AMH:
- ≥1.2 ng/mL considered normal ovarian reserve by POSEIDON criteria 5
- Age-adjusted interpretation is essential given progressive decline
High AMH (hyperresponse risk):
Important Clinical Considerations
Discordance between AMH and FSH occurs frequently (approximately 1 in 5 women), particularly in an age-dependent fashion 2. Among women with reassuring FSH (<10 IU/L), concerning AMH values (<0.8 ng/mL) were found in:
- 1 in 11 women under age 35
- 1 in 3 women over age 40 2
AMH detects ovarian dysfunction earlier than FSH - nearly 20% of at-risk patients have low AMH with normal FSH, meaning DOR would be missed using FSH screening alone 6. This is particularly relevant for young cancer survivors and women at risk for premature ovarian insufficiency.
Key advantages of AMH over FSH:
- Does not vary significantly by menstrual cycle day 7
- Not affected by exogenous estrogen or progesterone use 7
- Predicts biological age earlier than FSH 8
- Better correlates with antral follicle count 7, 3
Laboratory standardization matters: AMH testing has not been fully standardized across laboratories, so reference ranges are assay-specific 2. The values cited here primarily reflect Beckman Coulter Gen II and similar assays used in the referenced studies.